GLP-1 medications in Singapore: how they work, options, and what to consider

Interest in GLP-1 medications has grown quickly in Singapore, but so has confusion around what they are and when they may be appropriate.

From names like Ozempic and Wegovy to Saxenda, more people are exploring medically supported approaches to weight management.

At the same time, awareness has moved faster than understanding. Many recognise the names, but are less clear on how these medications work, who they are suitable for, and how to approach them safely.

There is a clear health context behind the increased interest.

Singapore’s National Population Health Survey 2024 reported that obesity among residents rose from 10.5% in 2019–2020 to 12.7% in 2023–2024, with the increase more pronounced among younger adults (Ministry of Health Singapore, 2024).

At the same time, doctors are seeing more patients asking about GLP-1 medications. Local reporting has highlighted rising enquiries, alongside concerns about misuse and unregulated access (Channel NewsAsia, 2025).

Taken together, this reflects a broader shift. More people are looking beyond general advice and exploring medically guided approaches.

GLP-1 receptor agonists are prescription medications that mimic a natural hormone in the body called glucagon-like peptide-1.

This hormone plays a role in regulating appetite, blood sugar levels, and digestion. These medications were first developed for managing type 2 diabetes, and some are now also approved for weight management in appropriate patients.

In Singapore, approvals and indications are regulated by the Health Sciences Authority (HSA), which determines the approved use of each medication.

GLP-1 medications do not directly target fat. Instead, they influence several underlying biological processes.

They act on the brain to reduce hunger signals, which may help lower overall food intake. They also slow gastric emptying, meaning food stays in the stomach longer and fullness may last longer after meals.

In addition, they support blood sugar regulation, which can help reduce fluctuations that may influence appetite and energy levels.

Clinical studies have shown that, in appropriate patients and under medical supervision, medications such as semaglutide can support average weight reductions of around 10 to 15 percent over time (Wilding et al., 2021).

In Singapore, different GLP-1 medications have different approved indications.

• Saxenda (liraglutide) is approved for weight management
• Ozempic (semaglutide) is approved for type 2 diabetes
• Wegovy (semaglutide) is approved for weight management in adults who meet specific criteria

These medications differ in dosing, indications, and suitability. They are not interchangeable, and not every option is appropriate for every individual.

GLP-1 medications are not general wellness products or over-the-counter solutions.

They are prescription treatments that require medical assessment. Suitability depends on factors such as body mass index, existing medical conditions, current medications, and overall metabolic health.

Some individuals may also experience side effects, particularly during the initial phase, which require monitoring.

The growing visibility of GLP-1 medications has led to a perception that they are a quick or standalone solution.

In practice, outcomes are more consistent when they are used within a structured, medically guided approach. This includes proper assessment, appropriate prescribing, and ongoing monitoring. Without this, patients may experience suboptimal results, poor adherence, or unnecessary risks.

Suitability depends on factors such as body mass index, existing medical conditions, and overall metabolic health. There are also potential side effects, particularly in the early stages, which require monitoring.

Recent local reporting has also highlighted the risks of obtaining such medications from unregulated sources, including unknown ingredients and misleading claims (Channel NewsAsia, 2025).

The safer approach is to start with a proper clinical assessment rather than self-selecting a treatment.

For those considering GLP-1 medications, starting with a proper medical review can provide clearer direction.

If you are exploring GLP-1 weight loss options in Singapore, a doctor-guided assessment can help. At HMI Medical Centre, weight management begins with a Weight & Metabolic Health Assessment. This allows doctors to understand your overall health and determine whether a structured care plan, which may include medication, is appropriate.

If you would like to better understand your options, speaking to a healthcare team can help you make a more informed decision.

1. Ministry of Health Singapore (2024). National Population Health Survey 2024. https://www.moh.gov.sg/newsroom/national-population-health-survey-2024-shows-singaporeans-are-adopting-healthier-lifestyles---but-rising-obesity-is-a-concern
2. Health Sciences Authority Singapore. Regulation and approval of therapeutic products in Singapore. https://www.hsa.gov.sg
3. Channel NewsAsia (2025). Illegal online sale of slimming products and prescription drugs raises concerns in Singapore. https://www.channelnewsasia.com/singapore/illegal-online-sale-weight-loss-patches-prescription-drugs-slimming-health-ozempic-5334041
4. Wilding, J.P.H. et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183